These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 20583198)

  • 1. Methodological issues in a meta-analysis.
    Crémieux P
    Hepatology; 2010 Jul; 52(1):395-6; author reply 396-7. PubMed ID: 20583198
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis C treatment, HAART and side effects.
    TreatmentUpdate; 2001; 13(7):7-8. PubMed ID: 11794865
    [No Abstract]   [Full Text] [Related]  

  • 3. Focus on hepatitis. Weight-based versus fixed-dose peginterferons.
    Shaw-Stiffel T
    IAPAC Mon; 2004 May; 10(5):178-80. PubMed ID: 15366103
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to issues raised in the Jansen/Reesink editorial.
    Silva M
    J Hepatol; 2007 Feb; 46(2):350-1. PubMed ID: 17161883
    [No Abstract]   [Full Text] [Related]  

  • 5. Second thoughts about secondary analyses.
    Ferenci P
    Dig Liver Dis; 2005 Oct; 37(10):805-7; author reply 808-9. PubMed ID: 16023903
    [No Abstract]   [Full Text] [Related]  

  • 6. Pegylated interferon-α2a versus pegylated interferon-α2b in hepatitis C: reappraisal of effectiveness on the basis of trial sequential analysis.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):246-8. PubMed ID: 24366456
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype.
    Thompson AJ; Muir AJ; Sulkowski MS; Patel K; Tillmann HL; Clark PJ; Naggie S; Fellay J; Ge D; McCarthy JJ; Goldstein DB; McHutchison JG
    Hepatology; 2010 Dec; 52(6):2243-4. PubMed ID: 20890887
    [No Abstract]   [Full Text] [Related]  

  • 8. Pegylated interferon-alpha2a and ribavirin in HIV-hepatitis C coinfected patients.
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):341-2. PubMed ID: 15490503
    [No Abstract]   [Full Text] [Related]  

  • 9. Quality of life with pegylated interferon therapy for hepatitis C.
    Brown RS
    Hepatology; 2002 Sep; 36(3):767-8; author reply 768. PubMed ID: 12198677
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse drug effects and pegylation.
    Wooten JM
    South Med J; 2011 Feb; 104(2):83-4. PubMed ID: 21206333
    [No Abstract]   [Full Text] [Related]  

  • 11. [Long-acting interferon: studies on pegylated interferon].
    Ma H; Wang H
    Zhonghua Gan Zang Bing Za Zhi; 2002 Feb; 10(1):78-9. PubMed ID: 11856520
    [No Abstract]   [Full Text] [Related]  

  • 12. Error in calculation of indirect analyses.
    Chou R; Chan BK
    J Viral Hepat; 2009 May; 16(5):376. PubMed ID: 19341421
    [No Abstract]   [Full Text] [Related]  

  • 13. [Primer treatment of acute and chronic hepatitis C].
    Daruich J; Fainboim H; Frider B
    Acta Gastroenterol Latinoam; 2006 Jun; 36 Suppl 1():S52-6; discussion S74-82. PubMed ID: 16862862
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictors of response of U.S. veterans to treatment for the hepatitis C virus.
    Riley TR
    Hepatology; 2008 Jan; 47(1):356; author reply 356-7. PubMed ID: 18161713
    [No Abstract]   [Full Text] [Related]  

  • 15. Peginterferon alfa-2b vs. peginterferon alfa-2a in the treatment of hepatitis C, is there any difference?
    Sierra F
    J Hepatol; 2007 Feb; 46(2):349; author reply 349-50. PubMed ID: 17161495
    [No Abstract]   [Full Text] [Related]  

  • 16. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients.
    Teta D; Lüscher BL; Gonvers JJ; Francioli P; Phan O; Burnier M
    Nephrol Dial Transplant; 2005 May; 20(5):991-3. PubMed ID: 15741205
    [No Abstract]   [Full Text] [Related]  

  • 17. Delaying HCV treatment in HIV-positive patients.
    Carter M
    IAPAC Mon; 2005 May; 11(5):147. PubMed ID: 16201045
    [No Abstract]   [Full Text] [Related]  

  • 18. Indian authority withdraws patent for interferon granted to Roche.
    Kay M
    BMJ; 2012 Nov; 345():e7499. PubMed ID: 23131676
    [No Abstract]   [Full Text] [Related]  

  • 19. [New perspectives in the treatment of viral hepatitis C: pegylated interferon alpha].
    Alric L; Cacoub P
    Rev Med Interne; 2001 Oct; 22(10):922-5. PubMed ID: 11695314
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment strategies of acute and chronic hepatitis C].
    Gładysz A; Inglot M
    Przegl Epidemiol; 2002; 56 Suppl 5():10-5. PubMed ID: 15553066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.